Luis Madero

40PUBLICATIONS
166CO-AUTHORS
Predictive and prognostic markersMolecular targetsChild and adolescent developmentCell physiologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Jul 25, 2026
Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma.

|Jul 23, 2026
Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

|Jun 10, 2026
SMARCB1 Deficiency in Tumors Confers a Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption.

|May 21, 2026
Assessing the Validity and Acceptability of an Adult Quality of Life Questionnaire, the EORTC QLQ-C30, for Adolescents With Cancer.

|Mar 30, 2026
Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Juliet Gray, Rebekah Weston, Simon Gates

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

Pageof 7

Frequent Collaborators

7 joint publications

Miguel F Segura

7 joint publications

Alba Rubio-San-Simón

5 joint publications

Francisco J Bautista

5 joint publications

Soledad Gallego Melcon